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Abstract

Experimental Methods

Demand for novel chemotherapeutic agents that treat Human African
Trypanosomaiasis (HAT) persists. A series of compounds sharing a 3,4’diphephyl
ether skeleton were prepared for a structure activity relationship (SAR) study
evaluating antitrypansomal drug candidates. Trypanocidal assays performed in vitro
by the Swiss Tropical and Public Health Institute identified a lead with an IC50 of 1.35
μg/mL analogous to a compound previously made in our laboratory. A slight
improvement in activity (10%) was observed when changing the molecular
substitution pattern from 4,4’ to 3,3’; however, the result is equivocal. Furthermore, in
vitro test results demonstrated the weakness of amides as side chain functional
groups, emphasizing the role of cationic moieties. The methods developed and
material produced from this research enables the rapid production of new
compounds to further investigate these observations.

3,4’-substituted diphenyl ether starting materials were synthesized from fluoro
or hydroxy substituted benzonitriles and benzaldydes using base-catalyzed
nucleophilic aromatic substitution. Then, general oxidative, amidative, and
reductive methods derivatized these precursors to testable products. The
chemical characterization of each included: melting point, nuclear magnetic
resonance spectroscopy, infrared spectroscopy, and elemental analysis.
Scheme 1. Synthesis of Starting Materials

The 3,4’ alcohol amine,15, exhibited the highest trypanocidal activity of the
compounds tested. This was expected since it’s chemical functionality is
analogous to known compounds made in our laboratory, G71ML and AM272.
Figure 1. Comparison of Diphenyl Ether Derivatives

Scheme 2. Derivatization of 1

The prepared derivatives have a 3,4’ substitution pattern
whereas our previous work focused on 4,4’ substituted compounds. The
enhanced activity of 15 relative to AM272 suggests that 3,4’ substituted
compounds may be superior in general. However, at present, the claim is
equivocal.
Another important finding is the apparent unsuitability of amides
as side chain functional groups. The amide analog of 15, 13, is an order of
magnitude less active. This emphasizes that cationic groups, such as the
protonated amine, are important structural features of active HAT drugs.

Introduction
Human African Trypanosomiasis (HAT) is a debilitating tropical disease caused by
the flagellar parasitic protozoa Trypanosoma Brucei. Left untreated, trypanosoma
parasites invade a patient’s brain and induce neurological changes such as sleep
disorder, ataxia, psychosis, coma, and ultimately death. Fortunately, aggressive
epidemiological intervention by the World Health Organization has limited the spread
of the disease in recent years. However, approximately 70 million people distributed
over a surface of 1.55 million km2 are estimated to be at differing levels of risk of
contracting HAT. While current drug treatments— suramine, pentamidine, nifurtumox,
and melarsoprol— are effective, they are also costly, inconvenient, and toxic.
Therefore, there is ongoing demand for novel chemotherapeutic agents that destroy
the parasite. Nonetheless, since HAT affects primarily impoverished populations,
pharmaceutical firms are disinterested in pursuing new HAT drug compounds.
Therefore, academic research is critical to HAT drug discovery.
Contemporary drug design attempts to exploit known biochemical
pathways associated with disease. The best therapeutic compounds, potent with
limited side effects, often modulate a specific and well understood process. Sadly, the
mechanism of action of current HAT treatments is poorly understood. Hence, HAT
drug development relies on modifying the chemical structure of compounds with
known efficacy. Systematically changing molecular shape, size, rigidity, or functional
groups can identify patterns that correlate chemical structure to biological activity.
Such experiments are called structure activity relationship (SAR) studies.
Internationally, the activity of anti-trypanosomal drugs is assayed by the
Swiss Tropical and Public Health Institute in Basel, Switzerland. They report the drug
concentration necessary to inhibit half of a parasite load, in vitro IC50 values,
measured in triplicate and referenced to melarsoprol (IC50 = 1 ng/mL) . A common
worldwide assay ensures that compared data is meaningful. Promising preliminary
compounds begin with low microgram per milliliter IC50 activities; whereas, strong
drug candidates require nanogram per milliliter IC50 activities.
The diversity of promising HAT drug candidates exhibiting ng/mL IC50 is
staggering. Many families of compounds have worked, so it’s sufficient to merely pick
one. This work is based on the lead compound G71ML (IC50 = 0.68 μg/mL), a parasubstituted diphenyl ether amino acid previously prepared in our laboratory.

Discussion

Scheme 3. Derivatization of 2

Scheme 3. Derivatization of 3 and 4

General Methods
(a) Nucleophilic Aromatic Substitution: K2CO3 (2 eq.), anhy. DMF, air free, 130 °C, 24 hr
(b) Cu(II) Bromide Oxidation: 70% TBuOOH (4 eq.), Cu(II)Br2 (0.1 eq.) acetonitrile, 23 °C, 1 hr.
(c) Sodium Borohydride Reduction: NaBH4 (3 eq.), methanol, 23°C, 1hr
(d) Caddick Reduction: NaBH4 (8 eq.), NiCl2∙2 H20 (0.2 eq.), Boc2O (2 eq.), 0 °C, 15 hr.
(e) Oxidative Amination: 30% H2O2 (1 eq.), K2CO3 (0.5 eq.), DMSO, 0 °C to 23°C, 1 hr
(f) Acidic Precipitation: Anhydrous HCl in ethyl acetate, 23°C, 5 min.

Results
Of the sixteen compounds prepared, four were sent to the Swiss TPHI for
trypanosomal assay: 13 (3-OH,4’-ONH2), 15 (3-OH,4’-CH2NH3+), 31 (3-OH,4’OH), and 41 (3-ONH2,4’-ONH2). The results are summarized in Table 1.
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Conclusion and Future Work
The preliminary findings of the SAR study support the notion of 3,4’
substitution patterns in HAT drugs. Diphenyl ether amide derivatives,
however, make poor drug compounds.
Future work will complete the synthesis and assay of the
best remaining candidates of the group (3-CH2NH3+, 4’-OH; 3-CH2NH3+, 4’CH2NH3+). Subsequently, the starting materials made during the project
will be applied to the rapid synthesis of other promising 3,4’ analogs.
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